After six companies raised approximately $720 million last week four more IPOs are planned this week seeking to raise $500 million plus.
Neon Therapeutics (NTGN) is developing therapies that target tumor neoantigens that are specific to individual tumors. The company currently has three candidates in development. Neon is planning a $100 million IPO.
Forty Seven (FTSV) founded by leading scientists at Stanford University who uncovered the fundamental role of CD47 in cancer evasion. The company is developing an antibody, 5F9, that is currently being studied in multiple Phase 1 and Phase 2 trials in various cancers, including non-Hodgkin’s lymphoma, colorectal cancer, ovarian cancer and acute myeloid leukemia as both monotherapy and in combination with approved therapies. The IPO is expected to raise up to $115 million.
Translate Bio (TBIO) is developing mRNA therapies to treat diseases caused by protein or gene dysfunction. The company has two drugs in development – one for cystic fibrosis and one for OTC deficiency (a liver disorder). Their IPO is expected to be in the $107 million range.
Tricida (TCDA) is focused on developing a drug for chronic kidney disease and metabolic acidosis. The drug, drug, TRC101, is a novel, non-absorbed polymer that is designed to bind hydrochloric acid in the GI tract and remove it from the body through excretion in the feces, thereby decreasing the total amount of acid in the body and increasing blood bicarbonate. The company is planning a $175 million IPO.